000220.Ks

The company maintains a strong liquidity position, with cash and equivalents amounting to KRW 29,090,832,980 and a current ratio of 1.64, indicating a solid ability to meet short-term obligations. The price-to-book ratio of 0.47 suggests that the company is trading at a discount relative to its book value, which may reflect market skepticism or undervaluation.

Profitability metrics show a return on equity (ROE) of 6.29% and a return on assets (ROA) of 3.93%, both of which are below the typical thresholds for high-performing pharmaceutical firms. The company's gross profit margin is 38.3%, and its operating margin is 7.1%, which are in line with industry norms but suggest limited pricing power or cost control advantages.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification may expose the company to higher operational and market risks, particularly in the event of regulatory changes or shifts in demand within its primary market.

Looking ahead, the company is projected to experience modest revenue growth, with a current fiscal year outlook indicating a slight increase in revenue. The company's capital expenditure is negative, suggesting a focus on cost reduction and asset optimization rather than expansion.

The company's risk profile is characterized by low liquidity and dilution risks, with no immediate filing-based flags detected. The debt-to-equity ratio of 0.22 indicates a conservative capital structure, and the absence of dilution potential suggests that the company is not currently issuing new shares to raise capital.

Recent financial filings and transcripts do not indicate any significant events or strategic shifts. The company's last actual EPS was 80.50 KRW, and its last actual revenue was 98,120,000,000 KRW, both of which are in line with its recent performance.